Compare DexCom, Inc. (DXCM) vs Veritone Inc (VERI) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Veritone (VERI) stock trades at $1.04, down 2.8% on the day, reflecting significant fundamental challenges. The company reported a net loss of $111.73M on $92.19M revenue for 2025, with a negative net margin of -123.76%. Technical indicators are mixed but lean bearish, with moving averages signaling a downtrend. Recent news is dominated by multiple class-action lawsuits alleging securities fraud related to revenue overstatements, with a key deadline of July 20, 2026.

The outlook is clouded by severe financial losses, ongoing litigation, and negative profitability metrics. While a high gross margin of 68.52% and a low P/S ratio of 0.86 present a potential value case, the extreme negative ROE of -349.36% and substantial cash burn from operations pose critical risks. Analyst consensus is split, but the overwhelming negative sentiment from recent legal news creates a highly uncertain investment environment.